-
公开(公告)号：US20230310323A1
公开(公告)日：2023-10-05
申请号：US18024733
申请日：2021-07-02
Applicant: ACCESS TO ADVANCED HEALTH INSTITUTE
Inventor： Ryan M. KRAMER , Emily VOIGHT , Alana GERHARDT , Michelle ARCHER
CPC classification number: A61K9/19 , A61K9/1075 , A61K39/12 , A61K2039/55555
Abstract: This disclosure provides thermostable, lyophilized compositions of nano structured lipid carrier (NLC) particles, methods of making the compositions, and methods of using the compositions for stimulating an immune response. The lyophilized compositions are in the form of cakes that form oil-in-water emulsions upon reconstitution. The compositions comprise NLC particles lyophilized in the presence of a cake-forming excipient. The compositions may be lyophilized with a bioactive agent, or the bioactive agent may be added after reconstitution. The bioactive agent may be RNA that encodes an antigen such as a viral protein. The thermostable, lyophilized compositions have uses as vaccine platforms or vaccines. The lyophilized cake maintains shape, structure, and color for at least 21 months stored at room temperature. Integrity and activity of the bioactive agent is maintained for at least eight months at room temperature and at least 21 months refrigerated.
-
公开(公告)号：US20220280640A1
公开(公告)日：2022-09-08
申请号：US17731671
申请日：2022-04-28
Applicant: ACCESS TO ADVANCED HEALTH INSTITUTE
Inventor： Christopher B. FOX
IPC: A61K39/39 , A61K35/76 , A61K39/04 , A61K39/12 , A61K45/06 , A61P31/06 , A61P31/12 , A61P33/04 , A61P35/00 , C07K14/705
Abstract: Stable aqueous formulations of adjuvant comprising a TLR7/8 agonist or a TLR4 agonist with a helper lipid that are adsorbed to alum are provided. Compositions and methods of using the formulations for stimulating an immune response are also provided.
-
公开(公告)号：US11801290B2
公开(公告)日：2023-10-31
申请号：US16333596
申请日：2017-09-15
Applicant: ACCESS TO ADVANCED HEALTH INSTITUTE
Inventor： Steven G. Reed , Malcolm S. Duthie
CPC classification number: A61K39/04 , A61K39/39 , A61K2039/55561 , A61K2039/55566 , A61K2039/55572 , A61K2039/55577
Abstract: Compositions and methods for preventing, treating and detecting leprosy are disclosed. The compositions generally comprise polypeptides comprising one or more Mycobacterium leprae antigens as well as polynucleotides encoding such polypeptides.
-
14.发明公开公开(公告)号：US20230194447A1
公开(公告)日：2023-06-22
申请号：US18170114
申请日：2023-02-16
Inventor： Yihua (Bruce) YU , Marc TARABAN , Christopher FOX
CPC classification number: G01N24/082 , G01N33/15
Abstract: A method of using the transverse relaxation rate (R2) of solvent NMR signal to noninvasively assess alum-containing products such as vaccines. This technique can be used for quality control in vaccine manufacturing (e.g., fill-finish step) to determine the evenness of alum filling level as well as extent of alum particle sedimentation in filled and sealed products.
-
公开(公告)号：US11585770B2
公开(公告)日：2023-02-21
申请号：US16593145
申请日：2019-10-04
Inventor： Yihua (Bruce) Yu , Marc Taraban , Christopher Fox
Abstract: A method of using the transverse relaxation rate (R2) of solvent NMR signal to noninvasively assess alum-containing products such as vaccines. This technique can be used for quality control in vaccine manufacturing (e.g., fill-finish step) to determine the evenness of alum filling level as well as extent of alum particle sedimentation in filled and sealed products.
-
Patent Agency Ranking
公开(公告)号：US11369672B2
公开(公告)日：2022-06-28
申请号：US16126285
申请日：2018-09-10
Applicant: ACCESS TO ADVANCED HEALTH INSTITUTE
Inventor： Steven G. Reed , Rhea N. Coler
IPC: A61K39/04 , A61K31/4409 , A61K31/496 , A61K39/39 , A61K45/06 , A61K39/00
Abstract: The present disclosure relates to methods and compositions for treating a active tuberculosis infection and methods and compositions for improving the efficacy of chemotherapy regimens against active tuberculosis infection. The present disclosure relates to methods of treating an active M. tuberculosis infection or an active infection resulting from reactivation of a latent infection in a mammal and to methods of improving the efficacy of chemotherapy regimens against active M. tuberculosis infection.
-
公开(公告)号：US12285483B2
公开(公告)日：2025-04-29
申请号：US18269284
申请日：2021-10-16
Applicant: ACCESS TO ADVANCED HEALTH INSTITUTE
Inventor： Christopher Bradford Fox
Abstract: This disclosure describes the use of solanesol as an adjuvant in vaccine compositions, as well as related prophylactic and therapeutic methods. Solanesol may be used to replace squalene in vaccine compositions with similar or superior immunostimulatory effects. Solanesol, which is solid at room temperature, may be formulated for use in vaccine compositions by heating above its melting temperature in an aqueous solution to form a dispersion.
-
18.发明公开公开(公告)号：US20240140997A1
公开(公告)日：2024-05-02
申请号：US18407367
申请日：2024-01-08
Applicant: ACCESS TO ADVANCED HEALTH INSTITUTE
Inventor： Steven G. REED , Rhea N. COLER , Gregory C. IRETON , Sylvie BERTHOLET
IPC: C07K14/35 , A61K39/04 , C07K14/285 , G01N33/569 , G01N33/68
CPC classification number: C07K14/35 , A61K39/04 , C07K14/285 , G01N33/5695 , G01N33/68 , A61K2039/55561
Abstract: The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp. antigens, and polynucleotides encoding such compositions and fusion proteins. The invention also relates to methods for their use in the treatment, prevention and/or diagnosis of tuberculosis infections.
-
公开(公告)号：US11344619B2
公开(公告)日：2022-05-31
申请号：US16098615
申请日：2017-05-11
Applicant: ACCESS TO ADVANCED HEALTH INSTITUTE
Inventor： Christopher B. Fox
IPC: A61K39/395 , A61K39/39 , A61K39/04 , A61K39/12 , C07K14/705 , A61K35/76 , A61K45/06 , A61P31/12 , A61P33/04 , A61P31/06 , A61P35/00 , A61K39/00
Abstract: Stable aqueous formulations of adjuvant comprising a TLR7/8 agonist or a TLR4 agonist with a helper lipid that are adsorbed to alum are provided. Compositions and methods of using the formulations for stimulating an immune response are also provided.
-
20.发明授权公开(公告)号：US12061160B2
公开(公告)日：2024-08-13
申请号：US18170114
申请日：2023-02-16
Inventor： Yihua (Bruce) Yu , Marc Taraban , Christopher Fox
CPC classification number: G01N24/082 , G01N33/15
Abstract: A method of using the transverse relaxation rate (R2) of solvent NMR signal to noninvasively assess if an alum-containing product, such as a vaccine, has been acceptably resuspended for use following transport and/or storage. This technique allows for the manufacturer and/or distributor and/or end user to monitor for unexpected stressors associated with transport and/or storage including, but not limited to, temperature fluctuations, pH changes, vigorous shaking during transportation, exposure to sunlight, and freezing.
-
-
-
-
-
-
-
-
-
Search Results
23
records
(took 0.018 seconds)
